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IMRT using simultaneous integrated boost 
(66 Gy in 6 weeks) with and without 
concurrent chemotherapy in head 
and neck cancer – toxicity evaluation 
Milan VOŠMIK1, Petr KORDAČ2, Petr PALUSKA1, Milan ZOUHAR1, 
Jiří PETERA1, Karel ODRÁŽKA1, Pavel VESELÝ1, Josef DVOŘÁK1 
SUMMARY:
AIM: To evaluate the toxicity of intensity-modulated radiotherapy with simultaneous integrated boost 
(SIB-IMRT) in head and neck cancer patients treated using a protocol comprising 66 Gy to the PTV1 
(planning target volume; region of macroscopic tumour) and 60 Gy and 54 Gy to the regions with high 
risk (PTV2) and low risk (PTV3) of subclinical disease in 30 fractions in six weeks.
MATERIAL AND METHODS: Between December 2003 and February 2006, 48 patients (median age 55; 
range 25–83, performance status 0–1) with evaluable non-metastatic head and neck cancer of various 
localizations and stages (stages: I–1; II – 8; III – 12; IV – 27 patients, resp.) were irradiated according 
to the protocol and followed (median follow-up 20 months; range 4–42). Ten patients underwent 
concurrent chemotherapy (CT) and in 15 patients the regimen was indicated postoperatively because 
of close or positive margins. In all cases the regimen was used as an alternative to conventional ra-
diotherapy (70 Gy in 7 weeks). The acute and late toxicities were evaluated according to RTOG and 
RTOG/EORTC toxicity scales, respectively. 
RESULTS: All patients fi nished the treatment without the need for interruption due to acute toxic-
ity. No patient experienced grade 4 toxicity. More severe acute toxicity was observed in patients 
with CT, but the most severe toxicity was grade 3. Grade 3 toxicity was observed in the skin, mucous 
membrane, salivary glands, pharynx/oesophagus and larynx in 8.4%, 35.4%, 39.6% and 2.1%, in the 
CT subgroup in 10%, 100%, 90%, 10%, respectively. The trend of impairment of acute toxicity by 
concurrent chemotherapy was statistically confi rmed by Fisher’s exact test (for mucous membranes 
p=0.000002 and pharyngeal/oesophageal toxicity p=0.0004). The most severe late toxicity was grade 
2 subcutaneous tissue (34.2%), mucous membrane (36.8%) and larynx (11.1%), grade 3 in salivary 
gland (2.6%) and grade 1 in skin (84.2%) and spinal cord (5.4%). The late toxicity was not increased 
by chemotherapy.
CONCLUSION: In light of the toxicity profi le we consider the presented regimen to be an alternative 
to conventional radiotherapy 70 Gy in 7 weeks. The addition of CT requires more intensive supportive 
care. 
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BACKGROUND
In the last few years intensity-modulated ra-
diotherapy (IMRT) has experienced a mas-
sive expansion in the radiotherapy of head and 
neck tumours. IMRT promises highly confor-
mal dose distributions around tumour targets 
and sparing of the critical organs involved. 
The possibility to spare eye bulbs, optic nerves 
and chiasma, brain stem and temporal lobes of 
brain dosimetrically favours the IMRT tech-
niques in nasopharyngeal, maxillary sinus 
and nasal cancers [1–3]. The other important 
advantage of IMRT in head and neck cancer is 
the possibility of parotid salivary gland spar-
ing. There is already suffi cient evidence of the 
clinical advantage of IMRT parotid-sparing 
technique after demonstration of a decrease 
of the risk of late xerostomia [4–7].  
IMRT offers a possibility of planned dose 
inhomogeneity in the planning target volume 
(PTV). The dose per fraction in the region with 
high risk of recurrence (region of tumour) is 
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higher than in other regions of the PTV. This 
principle is called simultaneous integrated 
boost (SIB, SIB-IMRT). The advocates of 
SIB-IMRT techniques emphasize the better 
conformality of irradiation in comparison to 
shrinking volumes techniques [8–10]. How-
ever, there is no widely accepted SIB-IMRT 
regimen for head and neck tumours. 
All patients in the present study were ir-
radiated by SIB-IMRT technique using a 
uniform fractionation regimen: a dose of 66 
Gy to the region of primary tumour and clini-
cal lymphadenopathy or tumour bed with 
positive or close margins, a dose of 60 Gy to 
the high-risk region of subclinical disease, 
and 54 Gy to the low-risk region of subclini-
cal disease in 30 fractions in six weeks. The 
regimen resembles the fractionation used in 
the RTOG H-0022 trial (multicentre phase II 
trial for oropharyngeal cancer T1-2, N0-1M0). 
The dose of 66 Gy in six weeks is biologically 
equivalent to 70 Gy in 7 weeks [9]. Concurrent 
chemotherapy was added based on current 
practice in conventional radiotherapy. In SIB-
IMRT clinical trials published so far there is 
limited information about the toxicity data for 
an SIB-IMRT uniform regimen equivalent to 
70 Gy in conventional radiotherapy. In com-
parison with RTOG H-0022 the present trial 
included patients with cancer sites in the head 
and neck region other than the oropharynx, as 
well as patients with locoregionally advanced 
cancer, who were ineligible for dose escala-
tion or another more toxic treatment approach 
(SIB-IMRT alone), and patients with concur-
rent chemotherapy.  
AIM
The aim of the present study was to evaluate 
the acute and late toxicity in head and neck 
cancer patients treated by SIB-IMRT regi-
men, comprising 66 Gy to the PTV1 (region 
of macroscopic tumour) and 60 Gy and 54 Gy 
to the regions with high risk (PTV2) and low 
risk (PTV3) of subclinical disease in 30 frac-
tions in six weeks, as well as the experience 
with concurrent chemotherapy.
MATERIALS AND METHODS
Patients
Between December 2003 and February 2006, 
51 patients with head nad neck cancer were ir-
radiated at our department using SIB-IMRT, 
regimen 66 Gy, 60 Gy and 54 Gy in 30 fractions. 
In three patients the treatment was terminated 
prematurely. In one patient the IMRT was in-
terrupted after a few initial fractions because 
of urgent tracheostomy. The patient then fi n-
ished the radiotherapy by conventional tech-
nique and the cause of acute suffocation was 
not interpreted in relation with radiotherapy. 
The two other patients refused to continue the 
radiotherapy after approximately half of the 
treatment. The acute toxicity in these patients 
did not exceed grade 2 in any organ. All three 
patients were excluded from evaluation.
All 48 evaluable patients were indicated for 
radiotherapy after histological verifi cation of 
carcinoma (mostly squamous cell carcinoma) 
in the head and neck region, and regional lymph 
node irradiation was indicated in all patients. 
All patients were primarily examined by an 
otolaryngologist (including endoscopy), and 
computer tomography of the head and neck, 
chest X-ray and liver ultrasound were indicat-
ed before treatment in all patients. Magnetic 
resonance was used in patients with tumours 
close to the skull base (mainly paranasal sinus 
and nasopharyngeal cancers). 
In all patients the regimen was an alterna-
tive to conventional radiotherapy with a dose 
of 70 Gy alone or with concurrent chemothera-
py. Originally, the regimen was indicated only 
in patients with early head and neck cancer 
stages, in patients with advanced disease, 
but unsuitable for dose escalation (age, other 
diseases) and in nasopharyngeal cancer with 
concurrent and adjuvant chemotherapy. Later, 
the regimen with concurrent chemotherapy 
was indicated in patients with locally and re-
gionally advanced cancer of localizations oth-
er than nasopharyngeal in the head and neck 
region.    
Twenty-three patients were irradiated with 
curative intent. In fi fteen cases the radiother-
apy was performed postoperatively because 
of positive or close histological margins. Ten 
patients were treated by concurrent radio-
therapy and chemotherapy (in all cases cispla-
tin 40 mg/m2 weekly). Patients with locally or 
regionally advanced disease treated by radio-
therapy alone were assessed as unsuitable for 
dose escalation or concurrent chemotherapy. 
Three patients with nasopharyngeal carcino-
ma were subsequently indicated for adjuvant 
chemotherapy (3 cycles of cisplatin 80 mg/m2 
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on day 1 and continual 5-fl uorouracil 1000 
mg/m2 on days 2–5 every four weeks).
One patient was treated by immunosup-
pressive therapy after kidney transplantation 
and one patient had chronic therapy by low-
dose methotrexate for gout until the fi rst week 
of radiotherapy. All patient and tumour char-
acteristics are described in Table 1.
Treatment planning and radiotherapy
Two planning systems were used – CadPlan 
Treatment Planning System (Varian Medi-
cal Systems Inc., Palo Alto, USA) with He-
lios module for inverse planning, and Eclipse 
(Varian Medical Systems Inc., Palo Alto, 
Gender (n):
   Male 41
   Female 7
Age (y):
   Median 55
   Range 25–83
Tumour site (n):
   Oropharynx 17
   Hypopharynx 11
   Larynx 9
   Nasopharynx 5
   Maxillary sinus 4
   Nasal cavity 2
Histological type
   Squamous cell carcinoma 43
   Undifferentiated carcinoma 3
   Adenocarcinoma 1
   Adenoid cystic carcinoma 1
Tumour stage (n):
   I 1
   II 8
   III 12
   IV 27
Radiotherapy (n):
   RT alone 23
   Concurrent RT and CT 10
   Postoperative RT 15
“Abbreviations: RT = radiotherapy; CT = chemotherapy.”
Table 1. Patient and tumour characteristics
USA). To defi ne planning target volumes and 
organs at risk we used planning computer 
tomography (slice gaps of 3–5 mm) with the 
intravenous application of contrast medium 
(if no contraindication); fusion with magnetic 
resonance was performed in some cases (na-
sopharyngeal, maxillary sinus and nasal cav-
ity cancers). During the treatment planning 
procedures and radiotherapy, the head and 
shoulders of patients are strictly immobilized 
by thermoplastic masks. 
Gross tumour volume (GTV), clinical target 
volume (CTV) and planning target volumes 
(PTV) were defi ned according to the Inter-
national Commission on Radiation Units and 
Measurements (ICRU) Report 50 recommen-
dations. PTV1 encompassed all macroscopic 
disease (= GTV) with a border (usually 1–2 
cm, minimally 0.5cm) for risk of microscopic 
spread (CTV) and set-up inaccuracies (PTV). 
PTV2 and PTV3 encompassed the regions 
(lymph nodes) at high risk and low risk of sub-
clinical spread of the disease (CTVs), respec-
tively, with 5mm margin. 
The following structures at risk were de-
fi ned and contoured: spinal cord, spinal cord 
+ 1 cm margin (for set-up inaccuracy risk), 
both parotid glands, brain stem and oral cav-
ity and posterior neck region as help struc-
tures. In patients with primary tumour local-
izations near the skull base (nasopharyngeal 
and maxillary sinus carcinomas), eye bulbs, 
optic nerves and chiasma were defi ned. Pre-
scription doses for PTVs and tolerance doses 
for organs at risk are presented in Table 2.
The equivalent uniform dose for PTVs was 
calculated according to Niemierko with pa-
rameter a=–8 [11].
EUD = (ΣΝ
ι=1
viDia)1/a  (1)
All patients were irradiated on a Clinac 
600C linear accelerator (Varian Medical Sys-
tems Inc., Palo Alto, USA) with dynamic mul-
tileaf collimator (2x26 leafs). The prescribed 
physical doses (66 Gy, 60 Gy and 54 Gy, re-
spectively) were delivered in 30 equivalent 
fractions in 6 weeks. 
The absolute dose and dose fl uences were 
verifi ed using fi lm dosimetry before treat-
ment. The set-up accuracy was checked mini-
mally once a week by a portal image system. 
The tolerable set-up error in set-up was 3 mm 
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in each axis. In case of set-up error of 3–5 mm 
the portal image was repeated next fraction. 
In case of set-up error of 3–5mm repeatedly 
or set-up error > 5mm the patient was resimu-
lated. We did not assess the necessity of re-
planning in any patient due to weight loss or 
tumour shrinkage.
Acute and late toxicity evaluation
All patients were examined by a radiation 
oncologist minimally once a week during the 
treatment. Subsequently, the patients were fol-
lowed every 3 months for the fi rst 3 years by 
a radiation oncologist and head/neck surgeon. 
The median follow-up of the whole group of 
patients was 20 months (4–42 months). 
Acute toxicity was evaluated according 
to the RTOG (Radiation Therapy Oncology 
Group) toxicity scale for skin, mucous mem-
brane, salivary glands, pharynx/oesophagus 
and larynx. All toxicity symptoms during the 
radiotherapy and three months after treat-
ment completion were included in the evalu-
ation. At the beginning of the trial it was not 
our institution’s policy to have prophylactic 
percutaneous endoscopic gastrostomy (PEG) 
placement. During the trial we changed the 
approach to supportive care and the patients 
who had primary swallowing diffi culties or 
who were planned for concurrent chemo-
therapy were indicated for prophylactic PEG 
placement. This non-uniformity in supportive 
care was the reason not to evaluate the weight 
loss separately.
Late toxicity was evaluated according to 
the RTOG/EORTC (European Organization 
for Research and Treatment of Cancer) Late 
Radiation Morbidity Scoring Schema for skin, 
subcutaneous tissue, mucous membranes, 
salivary glands, spinal cord and larynx. The 
function of salivary glands was assessed by 
quantitative pertechnetate scintigraphy (be-
fore radiotherapy, 3–6 months and more than 
one year after radiotherapy). The patients 
with persistence or early local recurrence 
(< 6 months) with subsequent palliative care 
or death by six months after starting radio-
therapy were excluded from the late toxicity 
evaluation (11 patients) as the local symptoms 
were distorted by the local progression of the 
disease. In one patient with persistence of la-
ryngeal cancer where salvage total laryngec-
tomy was performed, laryngeal late toxicity 
evaluation was not possible. The median fol-
low-up of the subgroup suitable for late toxic-
ity evaluation was 23 months (8–42 months). 
The overall survival, disease-free survival, 
locoregional control and distant metastasis-
free survival were not the primary aims of the 
present retrospective study due to heteroge-
neity in primary tumour site, stage and intent 
of radiotherapy. In addition, an analysis of lo-
cal and regional recurrences was made. 
Statistical analysis
The chi-square and Fisher’s exact test were 
used for a comparison of subgroups with and 
without concurrent chemotherapy. Kaplan-
Meier curves were calculated for locore-
gional-free survival, distant-metastasis-free 
survival, disease-free survival and overall 
survival.
RESULTS
The mean PTV1 (volume irradiated to dose 
of 66 Gy) was 289 ccm (range 83–825 ccm). 
The criteria for dose distribution (Table 2) 
with sparing of at least one parotid gland were 
met in 75% of patients. When a macroscopic 
tumour (primary tumour or lymphadenopa-
thy) was close to the parotid gland, it was not 
considered advisable to spare it. Higher mean 
doses in parotid glands were recorded among 
the fi rst twelve patients who were planned 
with the Cadplan planning system.
Structure Prescription
PTV66
PTV60
PTV54
Minimally 95% of prescribed dose 
to 95% of the volume. Maximal 
dose ≤ 115% of prescribed dose 
EUDPTV66(a=-8) equivalent to the 
prescribed dose GTV is in minimal-
ly 95% isodose
Spinal cord Maximum dose <44 Gy
Spinal cord + margin 1 cm Maximum dose <50 Gy
Brain stem Maximum dose <54 Gy
Parotid glands Minimally 50% of gland volume 
dose <30 Gy or mean dose <28 
Gy
Larynx (if it is not a part of PTV) 2/3 below 50 Gy
“Abbreviations: PTV – planning target volume; EUD – equivalent uniform dose; 
GTV – gross tumor volume.”
Table 2. Prescription doses for planning target volumes and 
tolerance doses for main organs at risk
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All 48 patients fi nished the therapy without 
the need for interruption due to acute toxicity. 
In patients with concurrent CT, the median 
number of administered cycles was 4 (range 
3–6). The reasons for discontinuation of che-
motherapy were leukopenia grade 3 (3 cases), 
elevation of serum creatinine (1 case), per-
formance status impairment (3 cases, mainly 
in connection with grade 3 pharyngeal/oe-
sophageal toxicity – loss of weight, parenteral 
hydration and nutritional support) and acute 
herpetic infection (1 case with 3 cycles of 
CT). 
No patient experienced unacceptable grade 
4 toxicity. We registered grade 3 toxicity in 
4 patients (8.4%) in skin toxicity (confl uent, 
moist desquamation), in 17 patients (35.4%) in 
mucous membrane toxicity (confl uent fi brin-
ous mucositis), in 19 patients (39.6%) in pha-
ryngeal toxicity evaluation (weight loss > 15% 
and severe dysphagia), and in 1 patient (2.1%) 
in laryngeal toxicity evaluation (whispered 
speech and marked arytenoid oedema).
More severe toxicity was observed in pa-
tients with concurrent chemotherapy, in a pa-
tient treated by immunosuppressive therapy 
and in a patient treated with low-dose metho-
trexate in the fi rst week of radiotherapy, but 
grade 3 toxicity at most. Grade 3 acute hypo-
pharyngeal/oesophageal toxicity was classi-
fi ed due to weight loss and severe dysphagia 
with the necessity of parenteral nutrition and 
rehydration or PEG usage. The statistical 
analysis confi rmed worse acute toxicity in 
the subgroup with concurrent chemotherapy 
in comparison to the subgroup without che-
motherapy, mainly in mucous membrane and 
pharyngeal/oesophageal toxicity. All acute 
toxicity data are shown in Table 3.
The highest grade of late toxicity accord-
ing to the RTOG/EORTC scale was grade 3 in 
salivary gland toxicity in one patient. In this 
patient with oropharyngeal cancer (but also 
with hepatic cirrhosis after hepatitis type C 
treated by interferon alpha) treated by radio-
therapy alone, and followed for 25 months, 
both parotids were spared according to the 
protocol, but there was noted severe mucous 
acute toxicity grade 3 during radiotherapy. 
The majority of patients reported an improve-
ment of xerostomia approximately one year 
after the radiotherapy. The subjective feeling 
of xerostomia in all patients corresponded to 
the results of quantitative pertechnetate scin-
tigraphy of salivary glands.
The late toxicity in any other organ did not 
exceed grade 3. In comparison of subgroups 
with and without concurrent chemotherapy 
there were not noticed statistical signifi cances 
except spinal cord toxicity. Two patients with 
nasopharyngeal cancer and multiple lymph-
adenopathy with concurrent chemotherapy 
presented transient Lhermitte’s sign (approx-
imately 4–12 months after radiotherapy). Both 
patients were young (36 and 42 years old) and 
they were treated by adjuvant chemotherapy 
because of nasopharyngeal primary localisa-
tion. The IMRT plans and portal images of 
these patients were checked (maximal set-up 
error 3.4 mm and 3.1mm, respectively), the 
Organ Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 p* p+
SKIN 0 26 (1)54.2% (10.0%)
18 (8)
37.5% (80.0%)
4 (1)
8.4% (10.0%) 0 0.005 1.0
MUCOUS 
MEMBRANE 0
4 (0)
8.4% (0.0%)
27 (0)
56.2% (0.0%)
17 (10)
35.4% (100.0%) 0 0.00001 0.000002
SALIVARY 
GLANDS 0
19 (0)
39.6% (0.0%)
29 (10)
60.4% (100.0%) - 0 0.004 -
PHARYNX & 
ESOPHAGUS 0
11 (0)
22.9% (0.0%)
18 (1)
37.5% (10.0%)
19 (9)
39.6% (90.0%) 0 0.001 0.0004
LARYNX 0 25 (1)52.1% (10.0%)
22 (8)
45.9% (80.0%)
1 (1)
2.1% (10.0%) 0 0.003 0.2
* p values of the chi-square test for radiotherapy vs. radiotherapy plus concurrent chemotherapy.
+p values of the Fisher exact test (RTOG Grade < 3 versus ≥ 3) for radiotherapy vs. radiotherapy plus concurrent chemotherapy
Table 3. Acute toxicity evaluation according to RTOG scale – absolute and relative numbers of patients (parenthesis – num-
ber of patients with concurrent chemotherapy)
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tolerance doses in spinal cord region were not 
exceeded (maximum spinal cord dose 38.9 and 
39.0 Gy, maximum spinal cord + 1cm margin 
dose 47.7. and 48.0 Gy, respectively), and no 
other cause of myelotoxicity was observed. 
In one patient a trismus persisted and in one 
patient normal swallowing was not restored. 
These patients are partly dependent on PEG 
intake. Observed late toxicity data are shown 
in Table 4.
To complete the information, the locore-
gional-free survival, distant-metastasis-free 
survival, disease-free survival and overall 
survival of the cohort were evaluated using 
Kaplan-Meier method (Figure 1). A subanal-
ysis of local recurrences according to site of 
primary tumour, tumour stage and modality 
combination was made (Table 5). All local re-
currences were in the region of the primary 
tumour (PTV1) except one, which was consid-
ered to be a marginal miss (in a patient with 
postoperative IMRT of maxillary sinus carci-
noma, the recurrence was close to the spared 
optic nerve in the orbital apex).  
DISCUSSION
The present study evaluated the toxicity of 
SIB-IMRT fractionation regimen 66 Gy – 60 
Gy – 54 Gy in 30 fractions in head and neck 
cancer patients. In the view of biological 
equivalency to conventional doses of 70 Gy, 60 
Gy and 50 Gy, respectively [9], the regimen 
was used as an alternative to conventional 70 
Gy in all patients. 
The early results of the RTOG H-0022 trial 
with the same fractionation regimen in early 
Fig. 1. Kaplan-Meier curves of overall survival, distant metastasis free surival, locoregional recurrence free survival and 
disease free survival.
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stages of oropharyngeal cancer were pub-
lished at the American Society for Therapeu-
tic Radiology and Oncology Annual Meeting in 
2006. Eisbruch et al. [12] reported results in 
67 evaluable patients: acute xerostomia grade 
2 and 3 in 49% and 1.5%, mucositis grade 3 
and 4 in 25% and 1.5% and skin toxicity grade 
3 and 4 in 10% and 0% of patients, respective-
ly. The frequencies for late xerostomia at me-
dian follow-up of 13.3 months after treatment 
started were 20% and 1.5% for grade 2 and 3, 
respectively.
However, at the same time this fraction-
ation scheme has to be considered inadequate 
for locally and regionally advanced head and 
neck cancers, as well as for postoperative 
radiotherapy in patients with positive mar-
gins and extracapsular spread of the disease. 
There are three possible approaches to en-
hance the radiobiological effect of radiother-
apy on the tumour in locally and regionally 
advanced disease. The most common prac-
tice is the use of a higher dose than 66 Gy in 
30 fractions (70 Gy or more) [13–15]. On the 
other hand, there are data showing that dose 
escalation has limits in acute reactions. Lauve 
et al. [13] concluded that the “maximal toler-
able dose” is 70.8 Gy in 30 fractions (dose per 
fraction 2.36 Gy). The acute toxicity in two 
patients irradiated to a dose of 73.8 Gy (dose 
Organ Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 p* p+
SKIN 6 (0)15.8% (0.0%)
32 (8)
84.2% (100.0%)
0 0 0 0.2 -
SUBCUTANE-
OUS TISSUE 
0 25 (4)
65.8% (50.0%)
13 (4)
34.2% (50.0%)
0 0 0.3 0.4
MUCOUS 
MEMBRANE
3 (0)
7.9% (0.0%)
21 (5)
55.3% (62.5%)
14 (3)
36.8% (37.5%)
0 0 0.6 1.0
SALIVARY 
GLANDS
9 (1) 
23.7% (12.5%)
23 (6)
60.5% (75.0%)
5 (1)
13.1% (12.5%)
1 (0)
2.6% (0%)
0 0.8 1.0
SPINAL 
CORD
36 (6)
94.6% 
(75.0%)
2 (2)
5.4% (25.0%)
0 0 0 0.005 -
LARYNX
8 (1)
22.2% 
(12.5%)
24 (6)
66.7% (75.0%)
4 (1)
11.1% (12.5%)
0 0 0.7 1.0
* p values of the chi-square test for radiotherapy vs. radiotherapy plus concurrent chemotherapy.
+p values of the Fisher exact test (RTOG Grade < 2 versus ≥ 2) for radiotherapy vs. radiotherapy plus concurrent chemotherapy
Table 4. Late toxicity evaluation according to RTOG/EORTC scale – absolute  and relative numbers of patients (parenthesis 
- number of patients with concurrent chemotherapy)
Group Locoregional 
recurrence %
Tumour site:
   Oropharynx 2/17 11.8
   Hypopharynx 7/11 63.6
   Larynx 3/9 33.3
   Nasopharynx 1/5 20.0
   Maxilary sinus 3/4 75.0
   Nasal cavity 1/2 50.0
Stage:
   I 0/1 0.0
   II 3/8 37.5
   III 2/12 16.6
   IV 12/27 44.4
Intent of radiotherapy:
   Radiotherapy alone 10/23 43.5
   Chemoradiotherapy 3/10 30.0
   Postoperative radiotherapy 4/15 26.7
Age (years):
   < 70 12/41 29.3
   ≥ 70 5/7 71.4
Total: 17/48 35.4
Table 5. Analysis of locoregional recurrences according to primary 
tumour site, stage of the disease, intent of radiotherapy and age.
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per fraction 2.46 Gy) required a treatment 
break and dose reduction. Butler et al. [16] 
earlier referred 20 patients irradiated in 25 
fractions in fi ve weeks to a total dose of 60 Gy 
and 50 Gy, respectively (dose per fraction 2.4 
Gy and 2.0 Gy, respectively). 80% of patients 
developed RTOG grade 3 acute mucositis and 
50% grade 3 pharyngitis. The high number of 
grade 3 acute side effects corresponds to the 
escalation of dose per fraction. Furthermore, 
there is still limited evidence that the higher 
dose per fraction cannot increase the late ef-
fect probability.
In conventional RT guidelines there is now 
a widely accepted standard – the use of con-
current chemotherapy. The analogical CT 
schemes can be considered to be useful in 
SIB-IMRT techniques, but there is a neces-
sity to confi rm it in clinical trials. Concurrent 
CT usually belongs to IMRT protocols for na-
sopharyngeal cancer [2,17]. The toxicity pro-
fi le in these trials was acceptable. Lee et al. 
[18] recently published a study with SIB-IM-
RT regimen with dose 70 Gy, 59.4 Gy and 54 
Gy in 33 fractions and concurrent CT (mostly 
two cycles of cisplatin 100 mg/m2 every 3–4 
weeks) in 41 patients with locally advanced 
oropharyngeal cancer. Acute grade 3–4 mu-
cous toxicity was reported in 66% of patients, 
and late xerostomia grade ≥ 2 was reported in 
12% of cases. 
The last option consists in a further altera-
tion of the regimen – hyperfractionation. How-
ever, there is only limited experience with the 
use of hyperfractionated SIB-IMRT in head 
and neck cancer [19]. 
The present trial confi rms the feasibil-
ity and very good tolerance of this regimen 
without concurrent chemotherapy in head and 
neck cancer. The addition of chemotherapy is 
supposed to be related to an increase in acute 
toxicity severity. Our acute toxicity data are in 
accordance with this hypothesis. The risk of 
acute toxicity grade ≥ 3 in conventional frac-
tionation was reported at generally less than 
25%, but in some studies up to 50% [20]. The 
alteration of fractionation causes higher inci-
dence of mucosal reactions (≥ 66%) [20] and in 
some cases the acute toxicity was the cause of 
discontinuation of clinical studies [21]. Simi-
larly, the limit of chemotherapy enhanced ra-
diotherapy is acute toxicity, mainly in CT en-
hanced altered radiotherapy regimens, where 
grade 3–4 mucosal toxicity can reach 100% 
[22]. The acute toxicity data in the present 
study are not different from estimated values 
experienced from conventional radiotherapy 
of 70 Gy in seven weeks.  
Concurrent CT shifts the acute toxicity to 
the levels of dose escalation trials. Similarly to 
conventional chemoradiotherapy, the adminis-
tration of concurrent chemotherapy in IMRT 
techniques requires intensive supportive care, 
mainly nutrition support. Inadequate support-
ive care may be the reason for administration 
of an incomplete number of CT cycles in some 
patients. 
The late toxicity was not unambiguously in-
creased by concurrent chemotherapy (Table 
4). The two cases of transient Lhermitte’s sign 
(grade 1 of late myelopathy) in the chemora-
diotherapy group cannot be explained simply 
by the addition of concurrent cisplatin. The ex-
act cause of the myelopathy in these patients 
is not clear, but the occurrence of Lhermitte’s 
sign is not unusual in nasopharyngeal cancer 
patients [23, 24]. All late toxicity data corre-
spond to data from previously published head 
and neck cancer IMRT trials. The use of quan-
titative pertechnetate scintigraphy has shown 
advantages in late xerostomia evaluation. 
Disease control was not the primary end-
point of this retrospective evaluation. The 
analysis of local recurrences noticed an un-
expected low local control in the hypopha-
ryngeal cancer subgroup. Histologically con-
fi rmed persistence of the disease was detected 
in three patients in stage II of hypopharyn-
geal cancer after radiotherapy alone (age 55, 
76 and 83 years, respectively), although the 
expected local control in early stages of hy-
popharyngeal cancer is 68–79% [25]. In other 
patients with local persistence or recurrence 
of hypopharyngeal cancer, radiotherapy was 
indicated for extensive inoperable disease. 
CONCLUSIONS
Although the cohort is a heterogeneous group 
of patients in terms of primary tumour loca-
tion, stage of the disease and radiotherapy 
approach (primary versus postoperative RT, 
concurrent CT), the present data confi rm the 
feasibility of this regimen in patients with 
head and neck cancer. The regimen without 
CT can be used in patients unable to receive 
a more intensive regimen (dose escalation, 
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chemoradiotherapy). Concurrent CT increases 
the acute toxicity similarly to conventional ra-
diotherapy and there are similar demands on 
supportive care as in conventional radiother-
apy with concurrent chemotherapy (mainly 
nutritional support). In light of the acute and 
late toxicity profi les we consider the presented 
regimen to be a possible alternative to conven-
tional radiotherapy (70 Gy / 7 weeks), although 
there is a necessity to confi rm the regimen 
with or without concurrent chemotherapy for 
each primary tumour localization and stage. 
It could be an alternative to conventional ra-
diotherapy also in view of local control and 
overall survival.
REFERENCES
01. Sultanem K, Shu HK, Xia P, et al. Three-dimen-
sional intensity-modulated radiotherapy in the 
treatment of nasopharyngeal carcinoma: the 
University of California-San Francisco expe-
rience. Int J Radiat Oncol Biol Phys 2000; 48: 
711–22.
02. Lee N, Xia P, Quivey JM ,et al. Intensity-modu-
lated radiotherapy in the treatment of nasopha-
ryngeal carcinoma: an update of the UCSF ex-
perience. Int J Radiat Oncol Biol Phys 2002; 53: 
12–22.
03. Huang D, Xia P, Akazawa P, et al. Comparison 
of treatment plans using intensity-modulated 
radiotherapy and three-dimensional conformal 
radiotherapy for paranasal sinus carcinoma. Int 
J Radiat Oncol Biol Phys. 2003; 56:158–68.
04. Eisbruch A, Ten Haken RK, Kim HM, Marsh 
LH, Ship JA. Dose, volume, and function rela-
tionships in parotid salivary glands following 
conformal and intensity-modulated irradiation 
of head and neck cancer. Int J Radiat Oncol Biol 
Phys 1999; 45: 577–87. 
05. Roesink JM, Moerland MA, Battermann JJ, 
Hordijk GJ, Terhaard CH. Quantitative dose-
volume response analysis of changes in parotid 
gland function after radiotherapy in the head-
and-neck region. Int J Radiat Oncol Biol Phys. 
2001; 51: 938–46.
06. Braam PM, Terhaard CH, Roesink JM, Raaij-
makers CP. Intensity-modulated radiotherapy 
signifi cantly reduces xerostomia compared with 
conventional radiotherapy. Int J Radiat Oncol 
Biol Phys. 2006; 66: 975–80.
07. Pow EH, Kwong DL, McMillan AS, et al. Xerosto-
mia and quality of life after intensity-modulated 
radiotherapy vs. conventional radiotherapy for 
early-stage nasopharyngeal carcinoma: Initial 
report on a randomized controlled clinical trial. 
Int J Radiat Oncol Biol Phys. 2006; 66: 981–91.
08. Dogan N, King S, Emami B, et al. Assessment of 
different IMRT boost delivery methods on target 
coverage and normal-tissue sparing. Int J Radiat 
Oncol Biol Phys 2003; 57: 1480–91. 
09. Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. 
Radiobiological considerations in the design of 
fractionation strategies for intensity-modulated 
radiation therapy of head and neck cancers. Int J 
Radiat Oncol Biol Phys 2000; 46: 619–30.
10. Wu Q, Manning M, Schmidt-Ullrich R, Mohan R. 
The potential for sparing of parotids and escala-
tion of biologically effective dose with intensity-
modulated radiation treatments of head and neck 
cancers: a treatment design study. Int J Radiat 
Oncol Biol Phys 2000; 46: 195–205. 
11. Niemierko A. A generalized concept of equiva-
lent uniform dose (abstract). Med Phys 1999; 26: 
1100.
12. Eisbruch A, Harris J, Garden A, et al. Phase II 
Multi-institutional study of IMRT for oropha-
ryngeal cancer (RTOG 00–22): Early results. 
Int J Radiat Oncol Biol Phys 2006; 66 (Suppl. 1): 
S46–7. 
13. Lauve A, Morris M, Schmidt-Ullrich R, et al. 
Simultaneous integrated boost intensity-modu-
lated radiotherapy for locally advanced head-
and-neck squamous cell carcinomas: II-clinical 
results. Int J Radiat Oncol Biol Phys 2004; 60: 
374–87. 
14. Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa 
C, Quivey JM. Intensity-modulated radiation 
therapy for head-and-neck cancer: the UCSF ex-
perience focusing on target volume delineation. 
Int J Radiat Oncol Biol Phys 2003; 57: 49–60.
15. Yao M, Dornfeld KJ, Buatti JM, et al. Intensity-
modulated radiation treatment for head-and-
neck squamous cell carcinoma-the University 
of Iowa experience. Int J Radiat Oncol Biol Phys 
2005; 63: 410–21.
16. Butler EB, Teh BS, Grant WH 3rd, et al. Smart 
(simultaneous modulated accelerated radiation 
therapy) boost: a new accelerated fractionation 
schedule for the treatment of head and neck can-
cer with intensity modulated radiotherapy. Int J 
Radiat Oncol Biol Phys. 1999; 45: 21–32.
17. Kam MK, Teo PM, Chau RM, et al. Treatment of 
nasopharyngeal carcinoma with intensity-modu-
lated radiotherapy: the Hong Kong experience. 
Int J Radiat Oncol Biol Phys. 2004; 60: 1440–50.
Księga1.indb   94 2008-08-05   11:37:25
Milan Vošmik • SIB-IMRT 66 Gy in 6 weeks in head and neck cancer
95REP PRACT ONCOL RADIOTHER • 2008 • 13/2/: 86–95
18. Lee NY, de Arruda FF, Puri DR, et al. A compari-
son of intensity-modulated radiation therapy and 
concomitant boost radiotherapy in the setting of 
concurrent chemotherapy for locally advanced 
oropharyngeal carcinoma. Int J Radiat Oncol 
Biol Phys. 2006 ; 66: 966–74.
19. Sanguineti G, Pou AM, Newlands SD. Acceler-
ated Hyperfractionated Intensity Modulated 
Radiotherapy (AHI) for T2-3 Oropharyngeal 
Carcinoma: Preliminary Results from a Phase 
I-II Study. Int J Radiat Oncol Biol Phys 2005; 63 
(Suppl.1): S380.
20. Trotti A. Toxicity in head and neck cancer: a re-
view of trends and issues. Int J Radiat Oncol Biol 
Phys 2000;47: 1–12.
21. Fowler JF, Harari PM, Leborgne F, Leborgne JH. 
Acute radiation reactions in oral and pharyngeal 
mucosa: tolerable levels in altered fractionation 
schedules. Radiother Oncol 2003; 69: 161–8.
22. Maguire PD, Meyerson MB, Neal CR, et al. Tox-
ic cure: Hyperfractionated radiotherapy with 
concurrent cisplatin and fl uorouracil for Stage 
III and IVA head-and-neck cancer in the com-
munity. Int J Radiat Oncol Biol Phys 2004; 58: 
698–704.
23. Cheng SH, Jian JJ, Tsai SY, et al. Long-term sur-
vival of nasopharyngeal carcinoma following 
concomitant radiotherapy and chemotherapy. Int 
J Radiat Oncol Biol Phys. 2000; 48:1323–30.
24. Lee SW, Back GM, Yi BY, et al. Preliminary re-
sults of a phase I/II study of simultaneous modu-
lated accelerated radiotherapy for nondissemi-
nated nasopharyngeal carcinoma. Int J Radiat 
Oncol Biol Phys. 2006; 65: 152–60.
25. Nakamura K, Shioyama Y, Sasaki T, et al. Chemo-
radiation therapy with or without salvage sur-
gery for early squamous cell carcinoma of the 
hypopharynx. Int J Radiat Oncol Biol Phys. 
2005; 62: 680–3.
Księga1.indb   95 2008-08-05   11:37:26
